| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.8 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.059 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.9 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.0088 | 0.9 |